Everyday healthcare providers are bombarded with emails and calls about new biosimilars entering the market. Choosing the best workhorse biosimilar requires a systemic, multidisciplinary approach. Learn how Scripps Health opted for a scheduled rotating review of four to five biosimilar compounds per quarter, along with a complete review of each compound annually and semi-annually for financial consideration. Reaching the goal required the health system to establish a working group, consisting of clinical pharmacists from both the inpatient and outpatient sites of care, experts from the prior authorization department, retail pharmacy, information technology and pharmacy administration. Presenters will share how they utilized available tools from their wholesaler, the GPO and commercial health plans to select workhorse and backup biosimilar compounds.
